Vertex Pharmaceuticals Incorporated: Cystic Fibrosis trials

The registry lists 125 Cystic Fibrosis studies with Vertex Pharmaceuticals Incorporated as lead sponsor. 4 are open to participants now and 80 have results posted.

Phase 1 31Phase 2 24Phase 3 62Phase 4 2No phase 9(a study in two phases counts in both)

Studies

Page 2 of 2. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Decentralized Study to Evaluate Physical Activity and Cough Frequency Using Wearable Technology in Cystic FibrosisCompletedNCT04923464
• ELX/TEZ/IVA Expanded Access Program for Cystic Fibrosis (CF) Patients With at Least One F508del MutationApproved for marketingNCT04702360
• VX-445/TEZ/IVA Expanded Access Program for Cystic Fibrosis (CF) Patients Heterozygous for F508del Mutation and a Minimal Function Mutation (F/MF Genotypes)Approved for marketingNCT04058210
• A Study Evaluating Safety and Pharmacokinetics of VX-440 in Combination With Tezacaftor/Ivacaftor in Healthy Adult SubjectsCompletedNCT03486236Phase 1
• Tezacaftor/Ivacaftor Combination Therapy Expanded Access Program for Patients 12 Years of Age and Older With Cystic FibrosisApproved for marketingNCT03278314
• A Study to Evaluate Safety and Pharmacokinetics of VX-659 in Healthy Subjects and in Adults With Cystic FibrosisCompletedNCT03029455Phase 1
• MAD Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Cavosonstat (N91115) in Healthy Subjects (SNO-9)CompletedNCT02934139Phase 1
• Study of Cavosonstat (N91115) in CF Patients Who Are Heterozygous for F508del-CFTR and a Gating Mutation and Being Treated With IvacaftorStatus unknownNCT02724527Phase 2
• A Study to Confirm the Long-term Safety and Effectiveness of Kalydeco in Patients With Cystic Fibrosis Who Have an R117H-CFTR Mutation, Including Pediatric PatientsCompletedNCT02722057
• Study of Cavosonstat (N91115) in Patients With CF Homozygous for the F508del-CFTR MutationCompletedNCT02589236Phase 2
• Observational Study of Outcomes in Cystic Fibrosis Patients With Selected Gating Mutations on a CFTR Allele (The VOCAL Study)CompletedNCT02445053
• Study of N91115 in Patients With Cystic Fibrosis Homozygous F508del-CFTR MutationCompletedNCT02275936Phase 1
• PK Study of N91115 in Cystic Fibrosis PatientsCompletedNCT02227888Phase 1
• An Open-Label, Phase 1 Study in Healthy Adult Subjects to Examine the Effects of Multiple-Dose Ciprofloxacin on Ivacaftor and VX-661 in Combination With IvacaftorCompletedNCT02015507Phase 1
• Phase 1, QT/QTC Interval Study in Healthy SubjectsCompletedNCT01910415Phase 1
• A Phase 1 Study to Investigate the Food Effect of Lumacaftor in Combination With IvacaftorCompletedNCT01899105Phase 1
• An Ocular Safety Study of Ivacaftor-Treated Pediatric Patients 11 Years of Age or Younger With Cystic FibrosisCompletedNCT01863238
• A Phase 1 Study to Examine the Drug-Drug Interaction of Ciprofloxacin, Itraconazole, and Rifampin on the Combination of Lumacaftor With Ivacaftor in Healthy Adult SubjectsCompletedNCT01768663Phase 1
• VX-770 Expanded Access ProgramApproved for marketingNCT01381289
• Drug-Drug Interaction Study of VX-770 and VX-809 in Healthy SubjectsCompletedNCT01216046Phase 1
• Study of VX-770 in Subjects With Moderate Hepatic Impairment and in Matched Healthy SubjectsCompletedNCT01208285Phase 1
• Study of VX-770 on DesipramineCompletedNCT01153542Phase 1
• Study of VX-770 on Midazolam and Rosiglitazone and the Effect of Fluconazole on VX-770CompletedNCT01060566Phase 1
• Study of VX-770 and Rifampin in Healthy Male SubjectsCompletedNCT01018368Phase 1
• Drug-Drug Interaction Study of VX-809 and VX-770 in Healthy SubjectsCompletedNCT00966602Phase 1